US2021300942A1PendingUtilityA1
Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
Assignee: SUNOVION PHARMACEUTICALS INCPriority: Feb 11, 2015Filed: Feb 19, 2021Published: Sep 30, 2021
Est. expiryFeb 11, 2035(~8.5 yrs left)· nominal 20-yr term from priority
A61P 25/00A61P 25/08A61P 25/20A61P 25/28A61P 25/30C07D 498/20A61P 25/22A61P 1/08C07D 231/56A61P 21/02C07D 498/04A61P 25/14A61P 29/00C07D 498/22A61P 7/10A61P 3/04C07D 498/14A61P 25/18A61P 27/02A61P 25/04A61P 25/24A61K 31/5383A61P 27/16A61P 25/16
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are compounds of Formula (I):and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 - 55 . (canceled)
56 . A process for preparing a compound of formula
or a salt thereof, comprising:
comprising
with 4-methylbenzenesulfonic acid to obtain
combining
and di-tert-butyl dicarbonate to form
resolving
into its enantiomers
and isolating
and deprotecting
to obtain
or a salt thereof.
57 . A process according to claim 56 , wherein said resolving is accomplished by chiral HPLC.
58 . A process according to claim 56 , further comprising combining
with lithium diisopropylamide to form a mixture, then combining the mixture with tert-butyl methyl(2-oxoethyl)carbamate to obtain
59 . A process according to claim 58 , further comprising combining
in 2-bromoethanol to obtain
60 . A process for preparing a compound of formula
or a salt thereof,
comprising:
a) combining
in 2-bromoethanol to obtain
b) combining
with lithium diisopropylamide to form a mixture, then combining the mixture with tert-butyl methyl(2-oxoethyl)carbamate to obtain
c) combining
with 4-methylbenzenesulfonic acid to obtain
d) combining
and di-tert-butyl dicarbonate to form
e) resolving
into its enantiomers
and isolating
and
f) deprotecting
to obtain
or a salt thereof.
61 . A process according to claim 60 , wherein said resolving in step e) is accomplished by chiral HPLC.
62 . A process for resolving a compound of formula
into its enantiomers, comprising:
a) combining
with 4-methylbenzenesulfonic acid to obtain
b) combining
and di-tert-butyl dicarbonate to form
c) resolving
into its enantiomers
e) deprotecting with acid to obtain
63 . The process according to claim 62 , further comprising isolating
64 . A process according to claim 62 , further comprising combining
with lithium diisopropylamide to form a mixture, then combining the mixture with tert-butyl methyl(2-oxoethyl)carbamate to obtain
65 . A process according to claim 64 , further comprising combining
in 2-bromoethanol to obtain
66 . A compound selected from:
or a salt thereof.
67 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 56 .
68 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 57 .
69 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 58 .
70 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 59 .
71 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 60 .
72 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 61 .
73 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 62 .
74 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 63 .
75 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 64 .
76 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 65 .
77 . A process for preparing a compound of formula
or a salt thereof, comprising:
combining
with 4-methylbenzenesulfonic acid to obtain
combining
and di-tert-butyl dicarbonate to form
resolving
into its enantiomers
and isolating
and deprotecting
to obtain
or a salt thereof.
78 . A process according to claim 77 , wherein said resolving is accomplished by chiral HPLC.
79 . A process according to claim 77 , further comprising combining
with lithium diisopropylamide to form a mixture, then combining the mixture with tert-butyl methyl(2-oxoethyl)carbamate to obtain
80 . A process according to claim 79 , further comprising combining
in 2-bromoethanol to obtain
81 . A process for preparing a compound of formula
or a salt thereof,
comprising:
a) combining
in 2-bromoethanol to obtain
b) combining
with lithium diisopropylamide to form a mixture, then combining the mixture with tert-butyl methyl(2-oxoethyl)carbamate to obtain
c) combining
with 4-methylbenzenesulfonic acid to obtain
d) combining
and di-tert-butyl dicarbonate to form
resolving
into its enantiomers
and isolating
and
f) deprotecting
to obtain
or a salt thereof.
82 . A process according to claim 81 , wherein said resolving in step e) is accomplished by chiral HPLC.
83 . The process according to claim 62 , further comprising isolating
84 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 77 .
85 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 78 .
86 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 79 .
87 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 80 .
88 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 81 .
89 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 82 .
90 . A compound of formula
or a pharmaceutically acceptable salt thereof, prepared by the process of claim 62 .
91 . The compound, or pharmaceutically acceptable salt thereof, prepared by the process of claim 83 .Join the waitlist — get patent alerts
Track US2021300942A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.